MLchartDataset catalogue

IMREG-1

Term · Oncology and biomedicine · MLC-T-ONC-014396

A low molecular weight fraction of human leukocyte dialysates with potential immunostimulatory activity. IMREG-1 is shown to augment and accelerate human delayed type hypersensitivity (DTH) to recall antigen in vivo, potentiate production of interleukin-2 (IL-2) and interferon gamma, and induce expression of IL-2 receptor in peripheral blood mononuclear cells. These effects are attributed to the peptides Tyr-Gly and Tyr-Gly-Gly, which are identical to the N-terminal end of the enkephalins. Studies in HIV patients have shown that this agent may delay progression to more serious disease and improve laboratory markers.

Table 1. Record
IdentifierMLC-T-ONC-014396
FieldOncology and biomedicine
ExpansionsIMREG 1
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-014396",
  "term": "IMREG-1",
  "field": "Oncology and biomedicine",
  "definition": "A low molecular weight fraction of human leukocyte dialysates with potential immunostimulatory activity. IMREG-1 is shown to augment and accelerate human delayed type hypersensitivity (DTH) to recall antigen in vivo, potentiate production of interleukin-2 (IL-2) and interferon gamma, and induce expression of IL-2 receptor in peripheral blood mononuclear cells. These effects are attributed to the peptides Tyr-Gly and Tyr-Gly-Gly, which are identical to the N-terminal end of the enkephalins. Studies in HIV patients have shown that this agent may delay progression to more serious disease and improve laboratory markers.",
  "expansions": [
    "IMREG 1"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/imreg-1/"
}

Record 9,138 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.